ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Rovalpituzumab tesirine

First Posted Date: 2017-03-22

Last Posted Date: 2021-08-03

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT03086239

Locations: 🇯🇵
National Cancer Ctr Hosp East /ID# 161432, Kashiwa-shi, Chiba, Japan
🇯🇵
Kyushu University Hospital /ID# 161430, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Kinki University -Osakasayama Campus /ID# 161431, Osakasayama-shi, Osaka, Japan

and more 2 locations

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Phase 1

Completed

Conditions: Advanced Solid Tumors
Hematologic Malignancies
Cancer

Interventions: Drug: ABBV-621
Drug: FOLFIRI
Drug: Bevacizumab
Drug: Venetoclax

First Posted Date: 2017-03-17

Last Posted Date: 2022-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 153

Registration Number: NCT03082209

Locations: 🇺🇸
Millennium Oncology /ID# 214981, Houston, Texas, United States
🇺🇸
Yale University /ID# 158029, New Haven, Connecticut, United States
🇺🇸
The University of Chicago Medical Center /ID# 158030, Chicago, Illinois, United States

and more 16 locations

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-368
Drug: ABBV-181

First Posted Date: 2017-03-07

Last Posted Date: 2022-04-28

Lead Sponsor: AbbVie

Target Recruit Count: 139

Registration Number: NCT03071757

Locations: 🇫🇷
Institut Gustave Roussy /ID# 165035, Villejuif Cedex, Val-de-Marne, France
🇫🇷
AP-HM - Hopital de la Timone /ID# 165036, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸
Carolina BioOncology Institute /ID# 160786, Huntersville, North Carolina, United States

and more 24 locations

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Placebo
Drug: Venetoclax
Drug: Cytarabine

First Posted Date: 2017-03-03

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 211

Registration Number: NCT03069352

Locations: 🇺🇸
H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States
🇺🇸
Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States
🇦🇷
Cemic /Id# 159676, Buenos Aires, Argentina

and more 106 locations

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/pibrentasvir

First Posted Date: 2017-03-03

Last Posted Date: 2019-03-04

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT03069365

Locations: 🇺🇸
Northwest Louisiana Nephrology /ID# 160652, Shreveport, Louisiana, United States
🇩🇪
Univ Johannes Gutenberg /ID# 160828, Mainz, Germany
🇵🇷
School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 160755, San Juan, Puerto Rico

and more 35 locations

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir + Pibrentasvir Pediatric Formulation
Drug: Glecaprevir/Pibrentasvir Adult Formulation

First Posted Date: 2017-03-01

Last Posted Date: 2023-05-09

Lead Sponsor: AbbVie

Target Recruit Count: 129

Registration Number: NCT03067129

Locations: 🇺🇸
Boston Childrens Hospital /ID# 157988, Boston, Massachusetts, United States
🇺🇸
Indiana University /ID# 158001, Indianapolis, Indiana, United States
🇧🇪
UZ Leuven /ID# 162174, Leuven, Belgium

and more 35 locations

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Topotecan
Drug: Rovalpituzumab tesirine
Drug: Dexamethasone

First Posted Date: 2017-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: AbbVie

Target Recruit Count: 444

Registration Number: NCT03061812

Locations: 🇺🇸
Georgia Cancer Center /ID# 160206, Atlanta, Georgia, United States
🇺🇸
Cedars-Sinai Medical Center /ID# 157102, Beverly Hills, California, United States
🇺🇸
Mitchell Cancer Institute /ID# 158151, Mobile, Alabama, United States

and more 192 locations

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2017-02-15

Last Posted Date: 2019-03-14

Lead Sponsor: AbbVie

Target Recruit Count: 60

Registration Number: NCT03053180

Locations: 🇷🇺
KOGBUZ Kirovsk Infect Hosp, Kirov, Russian Federation
🇷🇺
South-Ural State Med. Academy, Chelyabinsk, Russian Federation
🇷🇺
Specialized Clinical Infectiou, Krasnodar, Russian Federation

and more 4 locations

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: risankizumab

First Posted Date: 2017-02-09

Last Posted Date: 2024-12-11

Lead Sponsor: AbbVie

Target Recruit Count: 2170

Registration Number: NCT03047395

Locations: 🇺🇸
Total Skin and Beauty Dermatology Center /ID# 154000, Birmingham, Alabama, United States
🇺🇸
Great Lakes Research Group - Bay City /ID# 153998, Bay City, Michigan, United States
🇺🇸
Oregon Medical Research Center /ID# 154003, Portland, Oregon, United States

and more 230 locations

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: SC-006
Drug: ABBV-181

First Posted Date: 2017-01-30

Last Posted Date: 2020-02-20

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT03035279

Locations: 🇺🇸
University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States
🇺🇸
Mayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy